Market Cap 15.80M
Revenue (ttm) 460,000.00
Net Income (ttm) -5.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,260.87%
Debt to Equity Ratio 0.00
Volume 115,200
Avg Vol 108,950
Day's Range N/A - N/A
Shares Out 17.56M
Stochastic %K 57%
Beta 0.79
Analysts Strong Sell
Price Target $6.33

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH i...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
Shubeedoo
Shubeedoo Jul. 12 at 11:07 AM
$LEXX More like passed out investman
0 · Reply
Investmann
Investmann Jul. 11 at 7:59 PM
$LEXX sleeping giant
0 · Reply
Shubeedoo
Shubeedoo Jul. 11 at 7:12 PM
$LEXX Daily supply of stock at and under 90 cents
0 · Reply
LongLEXX
LongLEXX Jul. 11 at 6:51 PM
$LEXX @Traveller22 Liraglutide isn't part of the Australian study so the MTA wouldn't be waiting for results from this study if it was regarding Liraglutide. Our most recent Liraglutide results only came out last month, so lots of time to hear from someone on that front As for Tirzepatide it is in the Australian study because of great results we announced in March '25. If the MTA is waiting for the results from the study and it's regarding Tirzepatide then that info has not been announced yet as even preliminary findings. There's plenty of time to create some partnerships with both of these drugs.
0 · Reply
Traveller22
Traveller22 Jul. 11 at 6:32 PM
$LEXX you certainly could be right, and all shareholders (myself included) hope you are . However, the lack of interest by significant pharma companies to date after what we all think is good news released (since the MTA was announced with respect to liraglutide and tirzepatide) perhaps indicates pharmaco’s aren’t as impressed as we think they should be. At some point if nobody is interested in the outcomes the company can generate we have to conclude it’s not as valuable as hoped.
1 · Reply
LongLEXX
LongLEXX Jul. 11 at 6:24 PM
$LEXX I disagree that "having a better pill is not as big a deal as a pill that works". Neither SNAC or DehydraTECH are drugs. They are both delivery systems for drugs. The drug itself, Semaglutide, is the active part of the equation that treats the obesity and diabetes etc. SNAC helps drugs absorb into the stomach lining but DehydraTECH helps drugs absorb into the intestine and/ or mucosal linings like the inside of the mouth and throat. There are many delivery systems available and being investigated for oral medications which all try to minimize adverse reactions and maximize absorbtion. SNAC was the best choice at the time for Rybelsus with Semaglutide. It was chosen because Novo thought it was the best at delivering the drug. If DehydraTECH is shown to be better, perhaps in our current Australian clinical study, that could be huge for LEXX. Perhaps Novo would stop using SNAC. Or at the very least, another company requiring a delivery system for Semaglutide may choose us.
0 · Reply
Maxedout2025
Maxedout2025 Jul. 11 at 4:27 PM
$LEXX opportunity is knocking! https://www.cnbc.com/amp/2025/07/09/hims-hers-generic-semaglutide-novo-nordisk-ozempic-wegovy-canada.html
0 · Reply
Maxedout2025
Maxedout2025 Jul. 11 at 3:52 PM
$LEXX especially considering the Reduction in SIDE EFFECTS…. this should be a huge negotiating tool $NVO $LLY
0 · Reply
Traveller22
Traveller22 Jul. 11 at 3:48 PM
$LEXX I think the comparison to SNAC doesn’t necessarily equate here. Going from no pill to the first pill is a big step and was highly valuable. Going from a pill that works to a pill that works a bit better isn’t as big of a milestone. Dehydratech seems to be the first published oral with success with liraglutide and tirzepatide - I guess we’ll see if any of the companies are interested in that or if they are fully focused on future molecules in their R&D pipeline.
1 · Reply
Maxedout2025
Maxedout2025 Jul. 11 at 3:11 PM
0 · Reply
Latest News on LEXX
Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 5 weeks ago

Lexaria Attending BIO International Convention


Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 3 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4


Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 3 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing


Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 5 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide


Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 5 months ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway


Lexaria Releases Annual Letter from the CEO

Jan 30, 2025, 9:15 AM EST - 5 months ago

Lexaria Releases Annual Letter from the CEO


Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 7 months ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing


Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 7 months ago

Lexaria Forms New Scientific Advisory Board


Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 8 months ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments


Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Oct 9, 2024, 9:05 AM EDT - 9 months ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing


Lexaria Updates Current GLP-1 Market

Oct 8, 2024, 9:20 AM EDT - 9 months ago

Lexaria Updates Current GLP-1 Market


Lexaria Appoints Michael Shankman as Chief Financial Officer

Oct 1, 2024, 9:25 AM EDT - 10 months ago

Lexaria Appoints Michael Shankman as Chief Financial Officer


Lexaria Releases Strategic Letter from the Outgoing CEO

Sep 5, 2024, 10:00 AM EDT - 11 months ago

Lexaria Releases Strategic Letter from the Outgoing CEO


Lexaria Welcomes Industry Veteran as New CEO

Sep 5, 2024, 9:00 AM EDT - 11 months ago

Lexaria Welcomes Industry Veteran as New CEO


First Results from Lexaria's Second GLP-1 Human Pilot Study

Aug 27, 2024, 9:20 AM EDT - 11 months ago

First Results from Lexaria's Second GLP-1 Human Pilot Study


Positive Results from Lexaria's Molecular Characterization Study

Aug 19, 2024, 9:05 AM EDT - 11 months ago

Positive Results from Lexaria's Molecular Characterization Study


Lexaria Preparing For Strategic Growth

Jul 16, 2024, 9:20 AM EDT - 1 year ago

Lexaria Preparing For Strategic Growth


Shubeedoo
Shubeedoo Jul. 12 at 11:07 AM
$LEXX More like passed out investman
0 · Reply
Investmann
Investmann Jul. 11 at 7:59 PM
$LEXX sleeping giant
0 · Reply
Shubeedoo
Shubeedoo Jul. 11 at 7:12 PM
$LEXX Daily supply of stock at and under 90 cents
0 · Reply
LongLEXX
LongLEXX Jul. 11 at 6:51 PM
$LEXX @Traveller22 Liraglutide isn't part of the Australian study so the MTA wouldn't be waiting for results from this study if it was regarding Liraglutide. Our most recent Liraglutide results only came out last month, so lots of time to hear from someone on that front As for Tirzepatide it is in the Australian study because of great results we announced in March '25. If the MTA is waiting for the results from the study and it's regarding Tirzepatide then that info has not been announced yet as even preliminary findings. There's plenty of time to create some partnerships with both of these drugs.
0 · Reply
Traveller22
Traveller22 Jul. 11 at 6:32 PM
$LEXX you certainly could be right, and all shareholders (myself included) hope you are . However, the lack of interest by significant pharma companies to date after what we all think is good news released (since the MTA was announced with respect to liraglutide and tirzepatide) perhaps indicates pharmaco’s aren’t as impressed as we think they should be. At some point if nobody is interested in the outcomes the company can generate we have to conclude it’s not as valuable as hoped.
1 · Reply
LongLEXX
LongLEXX Jul. 11 at 6:24 PM
$LEXX I disagree that "having a better pill is not as big a deal as a pill that works". Neither SNAC or DehydraTECH are drugs. They are both delivery systems for drugs. The drug itself, Semaglutide, is the active part of the equation that treats the obesity and diabetes etc. SNAC helps drugs absorb into the stomach lining but DehydraTECH helps drugs absorb into the intestine and/ or mucosal linings like the inside of the mouth and throat. There are many delivery systems available and being investigated for oral medications which all try to minimize adverse reactions and maximize absorbtion. SNAC was the best choice at the time for Rybelsus with Semaglutide. It was chosen because Novo thought it was the best at delivering the drug. If DehydraTECH is shown to be better, perhaps in our current Australian clinical study, that could be huge for LEXX. Perhaps Novo would stop using SNAC. Or at the very least, another company requiring a delivery system for Semaglutide may choose us.
0 · Reply
Maxedout2025
Maxedout2025 Jul. 11 at 4:27 PM
$LEXX opportunity is knocking! https://www.cnbc.com/amp/2025/07/09/hims-hers-generic-semaglutide-novo-nordisk-ozempic-wegovy-canada.html
0 · Reply
Maxedout2025
Maxedout2025 Jul. 11 at 3:52 PM
$LEXX especially considering the Reduction in SIDE EFFECTS…. this should be a huge negotiating tool $NVO $LLY
0 · Reply
Traveller22
Traveller22 Jul. 11 at 3:48 PM
$LEXX I think the comparison to SNAC doesn’t necessarily equate here. Going from no pill to the first pill is a big step and was highly valuable. Going from a pill that works to a pill that works a bit better isn’t as big of a milestone. Dehydratech seems to be the first published oral with success with liraglutide and tirzepatide - I guess we’ll see if any of the companies are interested in that or if they are fully focused on future molecules in their R&D pipeline.
1 · Reply
Maxedout2025
Maxedout2025 Jul. 11 at 3:11 PM
0 · Reply
Bigfin
Bigfin Jul. 11 at 2:57 PM
$LEXX All the great news from Lexxy and the progress being made has fallen on a deaf market. Reminds me of the title of a Smiths album 'The world won't listen.' I'll be adding to my position as funds allow. Something to think about, Novo paid 1.8B for SNAC and D-Tech is better. What would our share price be if Lexx got a similar offer of 1.8B? To me, that is just the starting price. We also have an extensive patent portfolio, and don't forget we had fast tracked approval for blood pressure/heart disease drug and our epilepsy trials shows D-Tech was more effective than the other cannabinoid medication that Jazz Pharma bought for a fortune. Many avenues for revenue and possible partnerships. GLTA!
2 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jul. 11 at 2:31 PM
$LEXX $NVO $LLY $PFE $MRK Blocked for spam
0 · Reply
Maxedout2025
Maxedout2025 Jul. 11 at 1:40 PM
$LEXX Someone better come to the table pretty quick…….. MTA and Results should come soon! $NVO $LLY $PFE $MRK opportunity of a lifetime! Recap: https://finance.yahoo.com/news/lexarias-dehydratech-tirzepatide-oral-capsules-131500293.html
0 · Reply
Maxedout2025
Maxedout2025 Jul. 11 at 1:02 PM
0 · Reply
LongLEXX
LongLEXX Jul. 10 at 1:45 PM
$LEXX Pretty obvious when a large bidder won't pay the extra 2 cents that they're also the large seller!
0 · Reply
Maxedout2025
Maxedout2025 Jul. 10 at 12:33 PM
$LEXX Here we go!
1 · Reply
Shubeedoo
Shubeedoo Jul. 10 at 11:11 AM
$LEXX It was there, 47,000+. Helluva buy, if it had gotten hit.........thinking and hoping
0 · Reply
Maxedout2025
Maxedout2025 Jul. 9 at 4:48 PM
$LEXX Come on Invenomic Capital!! Squeeze the shorters out!!
0 · Reply
LongLEXX
LongLEXX Jul. 9 at 4:03 PM
$LEXX No one's falling for the cheap bid gag! Let's see some real bids!
1 · Reply
Maxedout2025
Maxedout2025 Jul. 9 at 1:49 PM
$LEXX IMO Management is Negotiating a deal…… They would want to make sure all the T’s are crossed and i’s dotted for both parties It’s July 9th…. Hopefully the SP starts to rise
0 · Reply
Shubeedoo
Shubeedoo Jul. 9 at 1:47 PM
$LEXX Well we got a nice 47,000 share bid. Let's see if it gets hit
0 · Reply
Makingmillions192
Makingmillions192 Jul. 9 at 12:56 PM
$LEXX What I want to see is solid consolidation around $1 until we get closer to fall. Feeling a Sept / October runner here
0 · Reply